This NIH funding opportunity seeks to support collaborative research that leverages biosamples and/or data from type 1 diabetes clinical studies or trials to advance understanding of the disease's etiology and pathogenesis. The ultimate goal is to uncover critical disease mechanisms that help delay or prevent type 1 diabetes. Projects should utilize samples or data from rigorously characterized clinical resources such as DPT-1, TrialNet, or TEDDY, ensuring documented access consistent with NIH sharing policies. Topics of interest include biomarkers, environmental triggers, autoimmunity, mechanistic studies using multi-omics, immune activity at various disease stages, therapeutic responses (especially immune modulation), age effects, and comorbid autoimmune conditions. Non-responsive projects include those proposing use of animal models, clinical trials with efficacy endpoints, or any use of restricted samples not permitting open data/publication in accordance with NIH policy.
This NIH funding opportunity seeks to support collaborative research that leverages biosamples and/or data from type 1 diabetes clinical studies or trials to advance understanding of the disease's etiology and pathogenesis. The ultimate goal is to uncover critical disease mechanisms that help delay or prevent type 1 diabetes. Projects should utilize samples or data from rigorously characterized clinical resources such as DPT-1, TrialNet, or TEDDY, ensuring documented access consistent with NIH sharing policies. Topics of interest include biomarkers, environmental triggers, autoimmunity, mechanistic studies using multi-omics, immune activity at various disease stages, therapeutic responses (especially immune modulation), age effects, and comorbid autoimmune conditions. Non-responsive projects include those proposing use of animal models, clinical trials with efficacy endpoints, or any use of restricted samples not permitting open data/publication in accordance with NIH policy.